Cns Pharmaceuticals Inc

Available to platforms
R StocksTrader

Cns Pharmaceuticals Inc (CNSP) on the NASDAQ Exchange

Company overview

Cns Pharmaceuticals Inc is a publicly listed company from USA with shares traded on NASDAQ under the ticker CNSP. This page provides a live view of market pricing and an interactive chart to follow short and long-term moves without manual refresh. The latest streaming quotes for CNSP are bid 5.99 USD and ask 6.28 USD.

Use the chart to review recent momentum, identify key price areas, and track how Cns Pharmaceuticals Inc is performing relative to your portfolio in 2025. If you are researching the instrument for trading or investing, add CNSP to your watchlist in R StocksTrader and compare it with other US and European shares, indices, and metals.

Key facts

  • Exchange: NASDAQ
  • Company: Cns Pharmaceuticals Inc
  • Ticker: CNSP
  • Country: USA
  • Bid5.99 USD
  • Ask6.28 USD
  • Quotes: real-time, auto-updated

Risk

Risk Warning: Past performance of CNSP does not predict future returns.

FAQ

Open a trading account at RoboForex, decide on the number of assets to buy, and then place an order for Cns Pharmaceuticals Inc (CNSP) in R StocksTrader. Create and verify your profile, fund the account, search for CNSP, and choose the instrument type available to you. Add CNSP to your Watchlist to track moves and manage open positions throughout 2025.

CNSP trades on NASDAQ and is issued by Cns Pharmaceuticals Inc. This page provides a live chart and continuously updated price data for the 2025 year so that you can follow intraday swings and longer trends. Before starting trading and placing orders, review trading hours, typical spreads, and fees in the terminal to make sure conditions for CNSP match your plan.

Quotes update automatically in real time. Current levels for CNSP are bid 5.99 USD and ask 6.28 USD. The spread is the difference between ask and bid and affects your effective entry and exit. Track CNSP in R StocksTrader and adjust your approach as market conditions change in 2025.